

Structural Features


- 20 membered macrolactone core
- 3 densely functionalized pyran rings
- ~ 11 stereocenters
- C₈ geminal methyls
- C₁₆ - C₁₇ trans olefin
- Differ in substitution at C₇ and C₂₀
- bryostatin 3 possess C₂₂ oxygen; butenolide
- bryostatin 16 and 17 contain a dihydropyran C ring

History

- **1968:** Jack Rudloe sends samples of *Bugula neritina* to NCI
- **1976:** bryostatin 1 identified as active component in extracts
- **1982:** George Pettit reports crystal structure of bryostatin 1
- **1990:** Masamune reports the total synthesis of bryostatin 7
- **1998:** Evans reports the total synthesis of bryostatin 2
- **2000:** Yamamura reports the total synthesis of bryostatin 3
- **2008:** Trost reports the total synthesis of bryostatin 16
- **2011:** Wender reports the total synthesis of bryostatin 9
- **2011:** Keck reports the total synthesis of bryostatin 1
- **2011:** Krische reports the total synthesis of bryostatin 7

- Bryostatin 1: R₁ = Ac, R₂ = O₂C(CH)₄(CH₂)₂Me
Bryostatin 2: R₁ = H, R₂ = O₂C(CH)₄(CH₂)₂Me
Bryostatin 4: R₁ = COCH₂CHMe₂, R₂ = O₂C(CH₂)₂Me
Bryostatin 5: R₁ = COCH₂CHMe₂, R₂ = OAc
Bryostatin 6: R₁ = CO(CH₂)₂Me, R₂ = OAc
Bryostatin 7: R₁ = Ac, R₂ = OAc
Bryostatin 8: R₁ = CO(CH₂)₂Me, R₂ = O₂C(CH₂)₂Me
Bryostatin 9: R₁ = Ac, R₂ = O₂C(CH₂)₂Me
Bryostatin 10: R₁ = Piv, R₂ = H
Bryostatin 11: R₁ = Ac, R₂ = H
Bryostatin 12: R₁ = CO(CH₂)₂Me, R₂ = O₂C(CH)₄(CH₂)₂Me
Bryostatin 13: R₁ = CO(CH₂)₂Me, R₂ = H
Bryostatin 14: R₁ = Piv, R₂ = OH
Bryostatin 15: R₁ = Ac, R₂ = O₂C(CH)₄CH(OH)Et

Bryostatin 3: R₁ = Ac, R₂ = O₂C(CH)₄(CH₂)₂Me



- Bryostatin 16: R₁ = Piv, X = H, Y = CO₂Me
Bryostatin 17: R₁ = Piv, X = CO₂Me, Y = H
Bryostatin 18,19, 20 not yet characterized

Bugula neritina



- Colonial Animal
- Individuals in a colony: Zooids
- Grow up to 15 cm in length
- Hermaphroditic
- Each zooid produces a single embryo
- Plot twist: bryostatins are actually produced from an uncultured symbiotic bacterium, *Endobugula sertula*
- believed that bryostatins protect developing larvae from predators
- 18g bryostatin 1 isolated from 10,000 gallons of wet animal ~ 14 tons or 12,700 Kg


Biosynthesis

1996: Kerr

- incubates *B. neritina* with radio labeled precursors
- Acetate, glycerol and S-adenosylmethionine (SAM)

2007: Haygood

- *E. sertula* consistently associated with *B. neritina*
- *E. sertula* vertically passed to next generation
- *E. sertula* eliminated with antibiotics
- *B. neritina* larvae devoid of bryostatin
- Entire PKS gene, *bryA*, identified and cloned
- Efforts to transfer biosynthetic machinery into other organisms are ongoing



Biology

Anticancer:

- 43 separate phase I and phase II:
- Melanoma, myeloma, acute myeloid leukaemia, colorectal, renal, prostate, head and neck, cervix, ovarian, breast, peritoneal, stomach, oesophagus, anus, and lung cancer

Anti HIV:

- Reactivates HIV-1 from latency (PKC dependent)

Cognition:




- "Appropriate doses" improves rats' performance in spatial water maze
- Rescues induced depressive behavior



No Phase III advancement:





- Dose-limiting toxicity: severe myalgias
- Lack of efficacy


Biochemistry

- bryostatins target Protein Kinase C
- Protein Kinase C (PKC)
 - Serine/threonine specific kinases
 - 8 PKC isoforms
 - Regulate: proliferation, differentiation, motility, adhesion, and apoptosis
- bryostatins bind to the C₁ domain of PKCs
- Triggers conformational change
- PKC becomes more lipophilic and translocates to membranes
- Membrane bound PKC phosphorylates target proteins













Ene-Yne Coupling









Synthesis of Southern Fragment
















Northern Fragment Synthesis








(±)-CSA, PhH, reflux



BnBr, NaHMDS, 5:1 THF:DMF, 0°C








TESCl, imidazole, DCM, 25°C





- Northern Fragment
- 2% Yield (16 steps)

Southern Fragment Synthesis





- .005% Overall Yield
- 1.1 mg isolated




bryostatin 1 $K_i = 1.35$ nM


- Wender develops pharmacophoric model
- C₁, C₁₉, C₂₆ oxygens spatially overlap with phorbol
- "Recognition domain" hypothesized

A ring construction

Acetalization




Prins




- $R_1 = \text{Me}$ ($K_i = 232$ nM)
- $R_1 = \text{C}_7\text{H}_{15}$ ($K_i = 3.4$ nM)
- $R_1 = \text{C}_{13}\text{H}_{27}$ ($K_i = 1.5$ nM)
- $R_1 = \text{Ph}$ ($K_i = 7$ nM)

- Simplified A and B rings do not lose affinity for PKC





- $R_1 = \text{H}$ ($K_i = 8$ nM)
- $R_1 = t\text{-Bu}$ ($K_i = 6.5$ nM)
- $R_1 = \text{Ph}$ ($K_i = 2.3$ nM)
- $R_1 = \text{Ph (p-Br)}$ ($K_i = 1.9$ nM)


- Intact A ring not necessary
- C₉ region could be used to modify pharmacokinetics /dynamics



- $K_i = 5.4$ nM
- 5 - membered B ring retains single digit nM affinity
- Selectively translocates 4 of 8 PKC isozymes






- No significant binding
- Recognition domain not sufficient by itself
- Macrocycle necessary






- "Picolog"
- $K_i = 0.35$ nM
- 100 fold Greater potency than bryostatin 1 in 24 of 35 cancer cell lines



Bryostatin 1: Retrosynthesis




12 steps





20 steps





Keck, 2011
- 31 Steps (LLS)
- 58 total steps

















- PMA (0.1, 1, 10, 100 nM)
- Bryo 1 (0.1, 1, 10, 100, 1000 nM)
- 13 (1, 10, 100, 1000 nM)
- 10 nM PMA + Bryo 1 (1, 10, 100, 1000 nM)
- 10 nM PMA + 13 (1, 10, 100, 1000 nM)

- PMA, a tumor promoter, increases attachment of U-937 leukemia cells in this assay




- Simple modification of A and B ring leads to tumor-promoting PMA activity




Synthesis of Southern Fragment




Synthesis of Northern Fragment





C-Allylation Via Transfer Hydrogenation




Hydrogen Auto-Transfer










Step 1: 64% Yield
Step 2: 75% Yield

- 1) [(*R*)-BINOL]POCH₂CO₂Me,
NaHMDS, THF, -78°C to 0°C
2) HF-Pyr, THF:H₂O (100:1),
35°C



- .00004 % Yield
- 1.7 mg

Bryostatin 7

Step 1: 93% Yield,
6:1dr
Step 2: 60% Yield